- Home
- SFST vs RIGL Comparison
SFST vs RIGL Comparison
Compare SFST & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SFST
- RIGL
- Stock Information
- Founded
- SFST 1999
- RIGL 1996
- Country
- SFST United States
- RIGL United States
- Employees
- SFST N/A
- RIGL N/A
- Industry
- SFST Major Banks
- RIGL Biotechnology: Pharmaceutical Preparations
- Sector
- SFST Finance
- RIGL Health Care
- Exchange
- SFST Nasdaq
- RIGL Nasdaq
- Market Cap
- SFST N/A
- RIGL 282.2M
- IPO Year
- SFST 1999
- RIGL 2000
- Fundamental
- Price
- SFST $35.38
- RIGL $15.43
- Analyst Decision
- SFST Buy
- RIGL Buy
- Analyst Count
- SFST 1
- RIGL 4
- Target Price
- SFST $44.00
- RIGL $31.13
- AVG Volume (30 Days)
- SFST 19.5K
- RIGL 215.6K
- Earning Date
- SFST 10-21-2024
- RIGL 11-05-2024
- Dividend Yield
- SFST N/A
- RIGL N/A
- EPS Growth
- SFST N/A
- RIGL N/A
- EPS
- SFST 1.70
- RIGL N/A
- Revenue
- SFST $88,995,000.00
- RIGL $130,201,000.00
- Revenue This Year
- SFST N/A
- RIGL $38.26
- Revenue Next Year
- SFST $13.55
- RIGL $24.21
- P/E Ratio
- SFST $20.83
- RIGL N/A
- Revenue Growth
- SFST N/A
- RIGL 7.48
- 52 Week Low
- SFST $24.98
- RIGL $7.10
- 52 Week High
- SFST $39.36
- RIGL $17.30
- Technical
- Relative Strength Index (RSI)
- SFST 69.23
- RIGL 56.98
- Support Level
- SFST $33.88
- RIGL $14.87
- Resistance Level
- SFST $34.61
- RIGL $16.85
- Average True Range (ATR)
- SFST 0.65
- RIGL 0.92
- MACD
- SFST 0.10
- RIGL -0.18
- Stochastic Oscillator
- SFST 96.44
- RIGL 46.48
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's lead drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.